Hepatitis B virus reactivation after ustekinumab treatment: Reply from authors

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 478-479

  Tsai, T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; PSORIASIS;

EID: 84894228619     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12613     Document Type: Letter

References (5)

1. Chiu HY, Chen CH, Wu MS, et al,. The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C. Br J Dermatol 2013; 169: 1295-303.
2. Torbenson M, Thomas DL,. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
3. Raimondo G, Allain JP, Brunetto MR, et al,. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
4. Feeney SA, McCaughey C, Watt AP, et al,. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 2013; 85: 597-601.
5. Ferraro D, Pizzillo P, Di Marco V, et al,. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int 2009; 29: 1171-7.